{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T13:25:16Z","timestamp":1791033916256,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.urology.2005.11.045","type":"journal-article","created":{"date-parts":[[2006,5,13]],"date-time":"2006-05-13T10:21:38Z","timestamp":1147515698000},"page":"1043-1048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"title":["Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism"],"prefix":"10.1016","volume":"67","author":[{"given":"Arthur L.","family":"Burnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinity J.","family":"Bivalacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter C.","family":"Champion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biljana","family":"Musicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2005.11.045_bib1","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/archinte.1980.00330220022011","article-title":"Priapism and impotence in homozygous sickle cell disease","volume":"140","author":"Emond","year":"1980","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.urology.2005.11.045_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0022-5347(17)38248-4","article-title":"Priapism associated with the sickle cell hemoglobinopathies","volume":"145","author":"Fowler","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.11.045_bib3","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1046\/j.1464-410X.2002.03022.x","article-title":"Priapism in sickle-cell disease","volume":"90","author":"Adeyoju","year":"2002","journal-title":"BJU Int"},{"issue":"suppl 5","key":"10.1016\/j.urology.2005.11.045_bib4","first-page":"S39","article-title":"Report of the American Foundation for Urologic Disease (AFUD) Thought Leader Panel for evaluation and treatment of priapism","volume":"13","author":"Berger","year":"2001","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.urology.2005.11.045_bib5","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/01.ju.0000087608.07371.ca","article-title":"American Urological Association guideline on the management of priapism","volume":"170","author":"Montague","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.11.045_bib6","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1097\/00005392-199805000-00065","article-title":"Hydroxyurea in the treatment of sickle cell associated priapism","volume":"159","author":"Al Jam\u2019a","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.11.045_bib7","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0022-5347(17)65731-8","article-title":"Priapism; reason for failure of therapy","volume":"83","author":"Hinman","year":"1960","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.11.045_bib8","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S0022-5347(17)41904-5","article-title":"Experience with 105 patients with priapism","volume":"140","author":"Winter","year":"1988","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.11.045_bib9","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/S0022-5347(01)67479-2","article-title":"High flow priapism associated with sickle cell disease","volume":"153","author":"Ramos","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.11.045_bib10","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0090-4295(96)00320-2","article-title":"High-flow priapism associated with Fabry\u2019s disease in a child","volume":"48","author":"Foda","year":"1996","journal-title":"Urology"},{"key":"10.1016\/j.urology.2005.11.045_bib11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0022-5347(17)44746-X","article-title":"Priapism","volume":"136","author":"Lue","year":"1986","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.11.045_bib12","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0022-5347(17)38445-8","article-title":"Recurrent prolonged erections and priapism as a sequela of priapism","volume":"145","author":"Levine","year":"1991","journal-title":"J Urol"},{"issue":"suppl 4","key":"10.1016\/j.urology.2005.11.045_bib13","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1038\/sj.ijir.3900592","article-title":"Priapism","volume":"12","author":"Melman","year":"2000","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.urology.2005.11.045_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.ju.0000046303.22757.f2","article-title":"Pathophysiology of priapism","volume":"170","author":"Burnett","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.11.045_bib15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/j.1939-4640.2002.tb02601.x","article-title":"Noncholinergic penile erection in mice lacking the gene for endothelial nitric oxide synthase","volume":"23","author":"Burnett","year":"2002","journal-title":"J Androl"},{"key":"10.1016\/j.urology.2005.11.045_bib16","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1073\/pnas.0407183102","article-title":"Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism","volume":"102","author":"Champion","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"suppl 1","key":"10.1016\/j.urology.2005.11.045_bib17","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1038\/sj.ijir.3901209","article-title":"Novel nitric oxide signaling mechanisms regulate the erectile response","volume":"16","author":"Burnett","year":"2004","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.urology.2005.11.045_bib18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0031-6997(24)01503-5","article-title":"Pharmacology of penile erection","volume":"53","author":"Andersson","year":"2001","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.urology.2005.11.045_bib19","doi-asserted-by":"crossref","first-page":"47581","DOI":"10.1074\/jbc.M206088200","article-title":"Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity","volume":"277","author":"Francis","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urology.2005.11.045_bib20","doi-asserted-by":"crossref","first-page":"9672","DOI":"10.1021\/bi025727+","article-title":"Allosteric activation of cGMP-specific, cGMP-binding phosphodiesterase (PDE5) by cGMP","volume":"41","author":"Okada","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.urology.2005.11.045_bib21","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1046\/j.1432-1327.2000.01297.x","article-title":"Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities","volume":"267","author":"Corbin","year":"2000","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.urology.2005.11.045_bib22","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1074\/jbc.M106562200","article-title":"Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells","volume":"277","author":"Rybalkin","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urology.2005.11.045_bib23","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1046\/j.1432-1327.2001.02233.x","article-title":"Allosteric sites of phosphodiesterase-5 (PDE5)","volume":"268","author":"Gopal","year":"2001","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.urology.2005.11.045_bib24","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/mol.56.1.124","article-title":"Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds","volume":"56","author":"Turko","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.urology.2005.11.045_bib25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2741\/1231","article-title":"Allosteric sites of phosphodiesterase-5 sequester cyclic GMP","volume":"9","author":"Kotera","year":"2004","journal-title":"Front Biosci"},{"key":"10.1016\/j.urology.2005.11.045_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/sj.ijir.3900802","article-title":"Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters","volume":"14","author":"Lin","year":"2002","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.urology.2005.11.045_bib27","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/01.ju.0000075500.11519.e8","article-title":"Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism","volume":"170","author":"Lin","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2005.11.045_bib28","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1124\/mol.104.010678","article-title":"Erection capability is potentiated by long-term sildenafil treatment","volume":"68","author":"Musicki","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.urology.2005.11.045_bib29","series-title":"Product Information","year":"1998"},{"key":"10.1016\/j.urology.2005.11.045_bib30","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0002-9343(02)01165-8","article-title":"Sildenafil relieves priapism in patients with sickle cell disease","volume":"113","author":"Bialecki","year":"2002","journal-title":"Am J Med"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429505016985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429505016985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:44:43Z","timestamp":1758764683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429505016985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0090429505016985"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2005.11.045","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2005.11.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}